Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Vanita R. Aroda, Lawrence Blonde, Richard E. Pratley
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 5, pp. 979-994
Open Access | Times Cited: 49

Showing 26-50 of 49 citing articles:

Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study
Genki Sato, Hiroshi Uchino, Takahisa Hirose
Diabetes Therapy (2024) Vol. 15, Iss. 9, pp. 2119-2130
Open Access | Times Cited: 2
The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide
Tovi Shapira‐Furman, Ayala Bar-Hai, Amnon Hoffman, et al.
Molecules (2024) Vol. 29, Iss. 16, pp. 3909-3909
Open Access | Times Cited: 2
Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk
Hanin Diab, Taylor Fuquay, Palika Datta, et al.
Nutrients (2024) Vol. 16, Iss. 17, pp. 2886-2886
Open Access | Times Cited: 2
Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery
Seho Kweon, Jun-Hyuck Lee, Seong-Bin Yang, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 5
Oral Drug Delivery Systems Applied to Launched Products: Value for the Patients and Industrial Considerations
Takayuki Yoshida, Hiroyuki Kojima
Molecular Pharmaceutics (2023) Vol. 20, Iss. 11, pp. 5312-5331
Closed Access | Times Cited: 5
Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study
Akira Mima, SAYUMI KIDOOKA, Takahiro Nakamoto, et al.
In Vivo (2023) Vol. 38, Iss. 1, pp. 308-312
Open Access | Times Cited: 5
Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis
X. Huang, Miaohui Wu, Jiaojiao Lin, et al.
Medicine (2024) Vol. 103, Iss. 21, pp. e38236-e38236
Open Access | Times Cited: 1
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Livia Basile, Rossella Cannarella, Stefano Iuliano, et al.
Minerva Endocrinology (2024) Vol. 49, Iss. 2
Closed Access | Times Cited: 1
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116471-116471
Closed Access | Times Cited: 1
An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits
Laxman Subedi, Arjun Dhwoj Bamjan, Subash Phuyal, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 637-655
Open Access | Times Cited: 1
THE NEWEST THERAPEUTICALLY APPROACH OF “DIABESITY” USING GLP-1 RA MOLECULES: IMPACT OF THE ORAL FORMULATION
Mariana Cornelia Tilinca
FARMACIA (2023) Vol. 71, Iss. 1, pp. 1-10
Open Access | Times Cited: 3
Oral semaglutide: an OASIS from injectables
Priya Manjoo, Arya M. Sharma
The Lancet (2023) Vol. 402, Iss. 10403, pp. 670-671
Closed Access | Times Cited: 2
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2
Rami A. Al‐Horani, Milad Chedid
Endocrine Metabolic & Immune Disorders - Drug Targets (2022) Vol. 23, Iss. 8, pp. 1046-1050
Open Access | Times Cited: 4
Bohemian Rhapsody of Future Drug Delivery Systems: Rational Changes Necessary for the Next Revolution
Kinam Park, Andrew Otte, Tonglei Li
Molecular Pharmaceutics (2024)
Closed Access
Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists
Alessandro Boianelli, Pär Nordell, Joseph Earl, et al.
Pharmaceutics (2024) Vol. 16, Iss. 10, pp. 1310-1310
Open Access
Recent Trends in Peptide Drug Discovery and Development
Harrison Y. R. Madge, Markus Muttenthaler
Royal Society of Chemistry eBooks (2024), pp. 23-49
Closed Access
Advanced Oral Breviscapine Sustained-Release Tablets for Improved Ischemic Stroke Treatment
Tingting Hao, Guangwei Jiang, Chenteng Lin, et al.
Biomaterials (2024) Vol. 316, pp. 123030-123030
Closed Access
Molecular Investigation of SNAC as an Oral Peptide Permeation Enhancer in Lipid Membranes via Solid-State NMR
Jing Ling, Ryan Schroder, W. Peter Wuelfing, et al.
Molecular Pharmaceutics (2024) Vol. 22, Iss. 1, pp. 459-473
Closed Access
Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia
Quanxiao Wang, Hongxing Huang, Peisheng Liang, et al.
Medical Oncology (2023) Vol. 41, Iss. 1
Closed Access | Times Cited: 1
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists
Elena Jiménez-Martí, Gema Hurtado-Genovés, María Aguilar-Ballester, et al.
Nutrients (2022) Vol. 14, Iss. 18, pp. 3775-3775
Open Access | Times Cited: 2

Mariana Cornelia Tilinca, Csilla Antal, Alina Balint, et al.
FARMACIA (2023) Vol. 71, Iss. 1
Open Access
Response to “Effects of Semaglutide on Cardiovascular Risk Factors and Eating Behaviors in Type 2 Diabetes”
Fnu Venjhraj, Mukesh Kumar, M. Sai Ram
Current Problems in Cardiology (2023) Vol. 48, Iss. 10, pp. 101802-101802
Closed Access
Drug delivery breakthrough technologies – A perspective on clinical and societal impact
Beate Bittner, Manuel Sánchez-Félix, Dennis Lee, et al.
Journal of Controlled Release (2023) Vol. 360, pp. 335-343
Closed Access
IMPACT OF SEMAGLUTIDE ON GLYCEMIC CONTROL AND POST-PRANDIAL GLUCOSE REDUCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Vitor Piassi, Juliana Yasmim Mendonça Leão de Oliveira, Rubia de Souza Olivo, et al.
International Journal of Health Science (2023) Vol. 3, Iss. 46, pp. 2-7
Open Access
Previous Page - Page 2

Scroll to top